The Phase 1 research will examine the safety and tolerability of escalating doses of VGX-100 in individuals with advanced solid tumours who have no other standard treatment plans both as a monotherapy and in addition when found in combination with various other anti-angiogenic agents. We are really proud to have completed the translation of VGX-100 from early discovery to the clinical advancement stage. We are focused on improving outcomes for individuals suffering from cancer, and think that VGX-100, when coupled with existing therapies could make a significant difference especially.‘The discovery of antiandrogen response elements was completely unforeseen,’ says principal investigator and OSUCCC – James researcher Qianben Wang, PhD, associate professor of molecular virology, immunology and medical genetics. He noted that antiandrogen agents are known to function by competing with androgens to bind to AR, inhibiting androgen-induced gene expression thus. ‘But we found that antiandrogens can also result in AR to bind to DNA sequences that are distinctly different from androgen response elements, and therefore regulate genes relevant to prostate cancer development,’ Wang says.